Navigation Links
Aisling Capital Announces Close of US$650M Life Sciences Fund

NEW YORK, Jan. 7 /PRNewswire/ -- Aisling Capital announced today that it raised US$650 million in committed capital for its newest life sciences fund, Aisling Capital III, LP. Aisling Capital will invest its third fund primarily in companies developing pharmaceutical, biopharmaceutical and medical products, as well as in businesses that provide drug development, manufacturing and other important services to the healthcare industry. With a total of over US$1.6 billion in committed capital under management, the Aisling Capital team will also continue to manage the Perseus-Soros BioPharmaceutical Fund, LP and Aisling Capital II, LP.

"We appreciate the support of our existing and new limited partners, particularly during these times of market turbulence," commented Dennis Purcell, Senior Managing Partner of Aisling Capital. Mr. Purcell added: "We believe the next several years will be a critical period for the life sciences industry, in which multiple forces will converge to create opportunities for the prepared investor."

The Aisling Capital team is comprised of individuals with a combination of clinical, transactional, operational and capital markets expertise, complemented by extensive networks in the life sciences industry. The team is led by Managing Partners Dennis Purcell, Steve Elms and Andrew Schiff, M.D. and newly promoted Partners Dov Goldstein, M.D., Anthony Sun, M.D. and Brett Zbar, M.D. Additionally, Josh Bilenker, M.D. has been promoted to Principal.

About Aisling Capital

Aisling Capital is a dedicated life sciences private equity firm with over US$1.6 billion under management. Headquartered in New York, Aisling Capital invests in both private and public companies utilizing a wide variety of investment structures. The Aisling Capital team's combination of clinical, operational and financial experience allows the firm to identify, execute and realize investments across the life sciences industry.

Web site:

SOURCE Aisling Capital
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
2. Rigel to Participate at the RBC Capital Markets Healthcare Conference
3. Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference
4. Micromet to Present at the RBC Capital Markets Healthcare Conference
5. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
6. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
7. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
8. Abaxis, Inc. to Present at the RBC Capital Markets 2008 Healthcare Conference
9. Medarex to Present at the RBC Capital Markets Healthcare Conference
10. Celator(R) Pharmaceuticals to Present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference
11. Jazz Pharmaceuticals Cancels Presentation Planned for November 19, 2008 at Lazard Capital Markets 5th Annual Healthcare Conference
Post Your Comments:
(Date:11/25/2015)... -- PharmAthene, Inc. (NYSE MKT: PIP) announced  today that its ... (Rights Plan) in an effort to preserve the value ... 382 of the Internal Revenue Code (Code). ... its NOLs could be substantially limited if the Company ... of the Code. In general, an ownership change occurs ...
(Date:11/25/2015)... 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... and CEO of Neurocrine Biosciences, will be presenting at ... New York . .   ... approximately 5 minutes prior to the presentation to download ... presentation will be available on the website approximately one ...
(Date:11/25/2015)... 2015 The Global Genomics ... professional and in-depth study on the current state ... ) , The report ... definitions, classifications, applications and industry chain structure. The ... markets including development trends, competitive landscape analysis, and ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... speaking at the following conference, and invited investors to ... NY      Tuesday, December 1, 2015 at 11.00 ... NY      Tuesday, December 1, 2015 at 11.00 ... Conference, New York, NY      Tuesday, ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
(Date:10/29/2015)... , October 29, 2015 ... biometric authentication company focused on the growing mobile ... wallet announces that StackCommerce, a leading marketplace to ... featuring the Wocket® smart wallet on StackSocial for ... ) ("NXT-ID" or the "Company"), a biometric authentication ...
(Date:10/27/2015)... In the present market scenario, security is ... industry verticals such as banking, healthcare, defense, electronic gadgets, ... for secure & simplified access control and growing rate ... of bank accounts, misuse of users, , and so ... laptops, and smartphones are expected to provide potential opportunities ...
Breaking Biology News(10 mins):